Labor Market Info
Outreach & Teaching
Testing & Assessment
Trabaja en el Gobierno
Directorio del Servicio Nacional de Empleo
Working in Canada
Education & Training
Scientist, Cancer Biology
Merrimack is a publicly traded biopharmaceutical company aspiring to be the leading provider of integrated medicines. Merrimack is advancing a suite of engineered therapeutics along with companion diagnostics designed to address significant unmet medical needs in the treatment of cancer and inflammation. Merrimack’s integrated medicines (Rx + Dx) are products of their paradigm changing Network Biology platform that integrates biology, engineering, and mathematical modeling to enable the mechanism-based discovery and development of therapeutics and diagnostics.
The first product of the Merrimack discovery and development platform, MM-121, is a human monoclonal antibody directed at ErbB3. MM-121 is currently in Phase I and Phase II trials in a variety of cancer indications and is being developed concurrently with a multiplexed diagnostic assay designed to identify patients that are predicted to respond to MM-121.
We are looking for an innovative scientist to elucidate the molecular mechanisms by which MM-121 interacts with standard-of-care therapies for our indications of interest and to help define the patient populations most likely to benefit from these combinations. This will have a direct impact on rationally designing the best treatment regimens in the clinic, along with the most predictive companion diagnostic. Responsibilities will include:
Designing and executing experiments aimed at identifying the pathways responsible for the observed synergy between MM-121 and standard-of-care drugs and the ability of MM-121 to overcome resistance to these drugs.
Identifying positive and/or negative biomarkers for these combination treatments.
Staying current with relevant literature and technological developments in the field.
Presenting research findings internally, as well as at relevant scientific meetings.
As part of a multidisciplinary team, this person will work closely with in vivo biologists to test in vitro findings in animal models. Interaction with computational modelers and clinicians will be essential for translating preclinical discoveries into the clinic.
Ph.D. or M.D./Ph.D. in a biological, biochemical, bioengineering, or biophysics discipline with at least 3 years of postdoctoral experience.
Extensive experience in dissecting cancer signaling pathways in vitro by chemical or biological means with specialization in one of the following areas: receptor tyrosine kinase signaling, apoptosis, cell cycle, or DNA damage. Knowledge of chemotherapy drugs and drug resistance mechanisms highly desirable.
State or Province
Terms and Conditions
©2000-2020 Candidate Seeker, Inc.
©1994-2020 Brolin Corporation